IM19 CAR-T cells
Phase 2Cell therapy
IM19 CAR-T cells is one of 93 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.
3
Indications
5
Total Trials
2
Active Trials
92
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
IM19 CAR-T cells
BBeijing Immunochina Medical Science & Technology Co., Ltd.
Phase 2
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma1 trial
Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
Recruiting·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1/2·NCT04440436·52 enrolled
Mantle Cell Lymphoma1 trial
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1/2·NCT05155215·68 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IM19 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details